DOI:
10.1055/s-00000017
Experimental and Clinical Endocrinology & Diabetes
LinksClose Window
References
Zelniker TA, Wiviott SD, Raz I. et al.
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and
renal outcomes in type 2 diabetes: A systematic review and meta-analysis of
cardiovascular outcome trials.
Lancet 2019;
393: 31-39
We do not assume any responsibility for the contents of the web pages of other providers.